The participants had relatively modest left ventricular enlargement and the trial was underpowered, with only 28 patients per treatment group.14 Consequently, we designed a larger, multicenter randomized, double-blind, placebo-controlled trial powered to investigate the effects of SGLT2 inhibition on left ventricular volumes in patients with HFrEF and type 2 diabetes or prediabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.